Nasdaq

Liquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling

Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating ...

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...
Nasdaq

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...